Risultati per: La carne alla griglia favorisce Alzheimer e diabete

Studio su Brain vede coinvolti anche ricercatori di Brescia

Ha mostrato di rallentare la malattia, costerà 26.500 dollari all’anno a persona

New England Journal of Medicine, Volume 388, Issue 1, Page 80-81, January 2023.

Molecola lega a recettore dell’ormone che regola zuccheri sangue

Le molecole che promuovono malattia legandosi a Rna messaggeri

Studio italiano, una moecola li salva da tossicità che li uccide

New England Journal of Medicine, Ahead of Print.

Da 2 a 15 dicembre in supermercati Coop.In Italia 600mila malati

Ma 65% vorrebbe ridurne consumo, domani V Giornata Nutrizione

Introduction
According to the World Alzheimer’s Report 2019, around 50 million people suffer from dementia, worldwide. Observational analysis revealed the existence of particular factors associated with the onset and progression of Alzheimer’s disease (AD). There are no international homogeneous principles for the early detection and evaluation of memory impairment and possible AD. This work aimed at (1) determining the prevalence of possible AD in the elderly residing in urban and rural regions in Cuba and (2) identifying the main factors that could significantly influence on its occurrence.

Methods and analysis
The study includes four neuropsychological tests (Clock Drawing Test, Mini-Mental Status Examination, Short Portable Mental Status Questionnaire, Cognitive and Non-Cognitive Alzheimer’s Disease Assessment Scale) and two scales (Clinical Dementia Rating and Global Deterioration Scale). Moreover, the protocol includes a survey with demographic and socioeconomic information, educational level, occupation, health, neuropsychological status of subjects, familial pathological history, comorbidities and lifestyles. The study will comprise a total of 1092 subjects aged ≥60, of both genders, and from every ethnic group settled in rural and urban areas. Primary outcomes: prevalence of possible AD. Secondary outcomes: correlation among risk and protective factors and AD, and comparison of the performance of neuropsychological tests and scales.

Ethics and dissemination
This research met the ethical codes of the Declaration of Helsinki. The Scientific Research Council of the Promoting Research Institute and the Ethics Committee of the Health Authorities approved the protocol. The proper written informed consent is also incorporated. The results of the survey will be published in scientific papers and shared with the Health Authorities of each municipality.

Circulation, Volume 146, Issue Suppl_1, Page A12707-A12707, November 8, 2022. Introduction:Contemporary HFrEF patients are older and have a higher prevalence of cognitive impairment compared to those studied in the original beta-blocker (BB) trials. While BB decrease mortality and morbidity in HFrEF, their use has been linked to higher fall risk and possibly acceleration of cognitive decline among older adults with Alzheimer’s Disease and Related Dementias (ADRD). The risk/benefit trade-off of beta blocker (BB) use in patients with HFrEF and dementia has not been examined.Methods:Using a 100% sample of patients enrolled in Medicare A, B and a 40% sample of D with ≥1 hospitalization for HFrEF between 2008 and 2018, we created a cohort of beneficiaries with HFrEF but no prior diagnosis of ADRD. We then subset to the population to those that developed ADRD in the year after their HFrEF hospitalization and compared BB use pre/post ADRD diagnosis and is association with outcomes using a time varying exposure.Results:The highest 1-year survival after ADRD diagnosis was observed among those continued on BB after ADRD diagnosis, regardless of whether they were on BB before (HR 0.427, 95% CI 0.406, 0.465, p